Assignment to an experimental group was conducted in an alternating fashion, based upon arrival time. The study consisted of two experimental groups. In the low dose group, participants received a dose of 800 mg/day. The high dose group received a dose of 1200 mg/day. CX-6258 molecular weight Study participants were asked to self-administer two to three (depending on their experimental group) soft-gelatin capsules daily containing either 400 mg of Resettin® (Resettin®/MyTosterone™; Triarco Industries, Wayne, NJ) or lecithin, which was used as the placebo. Participants were randomized into either the 800 mg/day or 1200 mg/day Resettin®/MyTosterone™

treatment group. After a 14-day treatment period, participants discontinued placebo or Resettin®/MyTosterone™ treatment for a consecutive 14 days. Following this 14-day washout period, participants were SYN-117 nmr crossed over within their respective group to either

Resettin®/MyTosterone™ or the lecithin placebo for 14 days. Blood was collected on days 0, 3, 7 and 14 days following the initiation of treatment. Serum hormone levels were collected and analyzed. Patterns of hormonal response were compared across the treatment groups in a pairwise manner. Researchers attempted to collect blood samples from all of the participants at approximately the same time of day in order to minimize circadian variations in serum hormone levels. Participants find more ADP ribosylation factor A total of forty sedentary, healthy men between the ages of 21 and 68 met inclusion criteria and were enrolled

for this study. Enrollment was voluntary, and participants signed informed consent statements in compliance with the Human Subjects Guidelines of Western Institutional Review Board and the American College of Sports Medicine. Participants were excluded from study if they had a history of smoking, pulmonary disease, hypertension, hepatorenal disease, musculoskeletal disorders, neuromuscular or neurological diseases, autoimmune diseases, cancer, peptic ulcers, or anemia. Participants were also excluded if they exhibited repeated signs of benign prostate hypertrophy, regularly consumed commercially available products containing saw palmetto or AX, were taking ergogenic levels of nutritional supplements that may affect muscle mass, such as creatine, or exhibited anabolic hormone levels, such as androstenedione or dehydroepiandrosterone. Participants taking prescription medication for a heart condition, pulmonary or thyroid problem were also excluded from the study. Participants on anti-hyperlipidemia, hypoglycemic, anti-hypertensive, endocrinologic, psychotropic, neuromuscular/neurological, or androgenic medications were also not invited to enroll in the study. After a 10-hour fast of all food or drink with caloric value along with a 48-hour rest from strenuous exercise, participants were phlebotomized.